A pilot, open study of @entity3756 in outpatients with @entity13217 ( @entity13217 ) or with a history of XXXX who responded but later relapsed.

@entity1 @entity308 @entity3756 @entity13217 @entity750
While most @entity308 @entity1 are prescribed a selective @entity750 reuptake inhibitor (SSRI) as an initial treatment, the use of SSRIs as a second or third-line treatment for @entity308 is not as prevalent. This trial assessed the efficacy of @entity3756 for @entity1 with @entity13217 ( @entity13217 ) or @entity1 with a history of @entity13217 who responded but later relapsed. Twelve @entity1 with @entity13217 who had not responded to a number of antidepressant trials (n=7), or had responded but subsequently suffered a relapse (n=5), were enrolled in an 8-week, open trial of @entity3756 . Both a completer analysis (n=6) and an intent-to-treat (ITT) analysis (n=12) were performed to evaluate @entity3756 response rates. Using a completer analysis, four @entity1 (66.6%) were classified as responders; one (16.7%) as a partial responder and one (16.7%) as a non-responder. An ITT analysis resulted in five (41.7%) @entity1 being classified as responders; one (8.3%) as a partial responder and six (50%) as non-responders. Of the four responders in the completer analysis, three (50%) achieved remission. Of the five responders in the ITT analysis, four (33.3%) achieved remission. Overall, two of seven (28.6%) non-responders and three of five (60.0%) relapsers responded to @entity3756 . The present results suggest the potential utility of @entity3756 for @entity1 with @entity13217 , or those with a history of @entity13217 who responded but later relapsed, and warrant larger, placebo-controlled studies to further explore the potential role of @entity3756 for such @entity1 .
